The state of Florida currently has 43 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension
NCT06864104
Recruiting
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who, despite taking 2 or more antihypertensive medications, have not achieved their target blood pressure (BP).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/30/2025
Locations: Jacksonville Center for Clinical Research, Jacksonville, Florida +2 locations
Conditions: Hypertension
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Lakeland Regional Health, Lakeland, Florida +3 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
NCT06865144
Recruiting
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: East Coast Institute for Research at Florida Eye Specialists, Jacksonville, Florida
Conditions: Primary Open Angle Glaucoma or Ocular Hypertension
Register for Updates
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435
Recruiting
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Excel Medical Clinical Trials, Boca Raton, Florida +4 locations
Conditions: Hypertension, Overweight or Obesity
Register for Updates
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530
Recruiting
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Excel Medical Clinical Trials, Boca Raton, Florida +4 locations
Conditions: Hypertension
Register for Updates
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
NCT03814317
Recruiting
This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/26/2025
Locations: University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville, Florida
Conditions: Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422
Recruiting
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Excel Medical Clinical Trials, Boca Raton, Florida +4 locations
Conditions: Hypertension
Register for Updates
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/17/2025
Locations: Clinovation Intl. Corp. ( Site 0108), Sebring, Florida
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Clear Vue Laser Eye Center, Lakeworth, Florida
Conditions: Glaucoma and Ocular Hypertension
Register for Updates
A Study of Mosliciguat in PH-ILD
NCT06635850
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/11/2025
Locations: Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC, Celebration, Florida
Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/30/2025
Locations: Advent Health, Orlando, Florida +1 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
NCT06785454
Recruiting
The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/12/2025
Locations: Nouvelle Clinical Research, Cutler Bay, Florida +3 locations
Conditions: Obstructive Sleep Apnea, Hypertension
Register for Updates